However, in a Chinese phase III trial conducted mostly for patients with B-viral HCC, those with BCLC-B or BCLC-C also benefitted from anti-PD-1 and anti-VEGF treatments relative to that from sorafenib treatment [37]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.